The Blocking of c-Met Signaling Induces Apoptosis through the Increase of p53 Protein in Lung Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose c-Met is an attractive potential target for novel therapeutic inhibition of human cancer, and c-Met tyrosine kinase inhibitors (TKIs) are effective growth inhibitors of various malignancies. However, their mechanisms in anticancer effects are not clear. In the present study,we investigated the possibility that blocking c-Met signaling induces p53-mediated growth inhibition in lung cancer. Materials and Methods The growth inhibitory effects of c-Met TKI (SU11274) on lung cancer cells and a xenograft model were assessed using the MTT assay, flow cytometry, and terminal deoxyribonucleotide transferase-mediated nick-end labeling staining. The role of p53 protein in the sensitivity of c-Met TKI (SU11274) was examined by Western blot analysis and immunohistochemistry. Results SU11274 significantly induced apoptosis in A549 cells with wild-type p53, compared with that in Calu-1 cells with null-type p53. SU11274 increased p53 protein by enhancing the stability of p53 protein. Increased p53 protein by SU11274 induced up-regulation of Bax and PUMA expression and down-regulation of Bcl-2 expression, subsequently activating caspase 3. In p53 knock-out and knock-in systems, we confirmed that SU11274 caused apoptosis through the p53-mediated apoptotic pathway. Likewise, in the A549 xenograft model, SU11274 effectively shrank tumor volume and induced apoptosis via increased p53protein expression. Blocking c-Met signaling increased the level of p53 protein. Conclusion Our finding suggested that p53 plays an important role in SU11274-induced apoptosis, and p53 status seems to be related to the sensitivity to SU11274 in lung cancer.
Abstract
Purpose c-Met is an attractive potential target for novel therapeutic inhibition of human cancer, and c-Met tyrosine kinase inhibitors (TKIs) are effective growth inhibitors of various malignancies. However, their mechanisms in anticancer effects are not clear. In the present study,we investigated the possibility that blocking c-Met signaling induces p53-mediated growth inhibition in lung cancer. Materials and Methods The growth inhibitory effects of c-Met TKI (SU11274) on lung cancer cells and a xenograft model were assessed using the MTT assay, flow cytometry, and terminal deoxyribonucleotide transferase-mediated nick-end labeling staining. The role of p53 protein in the sensitivity of c-Met TKI (SU11274) was examined by Western blot analysis and immunohistochemistry. Results SU11274 significantly induced apoptosis in A549 cells with wild-type p53, compared with that in Calu-1 cells with null-type p53. SU11274 increased p53 protein by enhancing the stability of p53 protein. Increased p53 protein by SU11274 induced up-regulation of Bax and PUMA expression and down-regulation of Bcl-2 expression, subsequently activating caspase 3. In p53 knock-out and knock-in systems, we confirmed that SU11274 caused apoptosis through the p53-mediated apoptotic pathway. Likewise, in the A549 xenograft model, SU11274 effectively shrank tumor volume and induced apoptosis via increased p53protein expression. Blocking c-Met signaling increased the level of p53 protein. Conclusion Our finding suggested that p53 plays an important role in SU11274-induced apoptosis, and p53 status seems to be related to the sensitivity to SU11274 in lung cancer.
참고문헌 (25)
- Bottaro DP, "Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product", Science, 251, pp.802~804 (1991)
- Furge KA, "Met receptor tyrosine kinase : enhanced signaling through adapter proteins", Oncogene, 19, pp.5582~5589 (2000)
- Christensen JG, "c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention", Cancer Lett, 225, pp.1~26 (2005)
- Engelman JA, "MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling", Science, 316, pp.1039~1043 (2007)
- Eder JP, "Novel therapeutic inhibitors of the c-Met signaling pathway in cancer", Clin Cancer Res, 15, pp.2207~2214 (2009)
- Ma PC, "Downstream signalling and specific inhibition of c-MET", HGF pathway in small cell lung cancer : implications for tumour invasion, 2007, pp.97, 368~377
- Puri N, "A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts", Cancer Res, 67, pp.3529~3534 (2007)
- Trotman LC, "PTEN and p53: who will get the upper hand?", Cancer Cell, 3, pp.97~99 (2003)
- Freeman DJ, "PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and-independent mechanisms", Cancer Cell, 3, pp.117~130 (2003)
- Mayo LD, "A phosphatidylinositol 3-kinase", Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus, 2001, pp.98, 11598~11603
- Wu X, "The p53-mdm-2 autoregulatory feedback loop", Genes Dev, 7, pp.1126~1132 (1993)
- Moumen A, "Met acts on Mdm2 via mTOR to signal cell survival during development", Development, 134, pp.1443~1451 (2007)
- Rong S, "Met proto-oncogene product is overexpressed in tumors of p53-deficient mice and tumors of Li-Fraumeni patients", Cancer Res, 55, pp.1963~1970 (1995)
- Peruzzi B, "Targeting the c-Met signaling pathway in cancer", Clin Cancer Res, 12, pp.3657~3660 (2006)
- Ma PC, "c-Met : structure, functions and potential for therapeutic inhibition", Cancer Metastasis Rev, 22, pp.309~325 (2003)
- Christensen JG, "A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo", Cancer Res, 63, pp.7345~7355 (2003)
- Lutterbach B, "Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival", Cancer Res, 67, pp.2081~2088 (2007)
- Ryan KM, "Regulation and function of the p53 tumor suppressor protein", Curr Opin Cell Biol, 13, pp.332~337 (2001)
- Momand J, "MDM2 : master regulator of the p53 tumor suppressor protein", Gene, 242, pp.15~29 (2000)
- Fritsche M, "Induction of nuclear accumulation of the tumorsuppressor protein p53 by DNA-damaging agents", Oncogene, 8, pp.307~318 (1993)
- Seiwert TY, "The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma", Cancer Res, 69, pp.3021~3031 (2009)
- Zimmer Y, "Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274", Cancer Lett, 289, pp.228~236 (2010)
- Xiong L, "A novel role for IGF-1R in p53-mediated apoptosis through translational modulation of the p53-Mdm2 feedback loop", J Cell Biol, 178, pp.995~1007 (2007)
- Zhou BP, "HER-2", neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation, 2001, pp.3, 973~982
- Smith TA, "Influence of chemoresistance and p53 status on fluoro-2-deoxy-D-glucose incorporation in cancer", Nucl Med Biol, 37, pp.51~55 (2010)